New research has found evidence that a novel stem cell treatment, using mRNA technology encapsulated into nanoparticles (LNP) that was successfully used to produce the COVID-19 vaccines, may boost the natural repair mechanism of the liver to regress the diseased tissue caused by either an acute or chronic liver injury. Researchers identified a specific receptor present on the stem cells which can be recognized and activated by the ligand protein called vascular endothelial growth factor A (VEGFA).
